|1.||Khalil, M H: 5 articles (08/2002 - 08/2000)|
|2.||Katz, D H: 3 articles (08/2001 - 08/2000)|
|3.||Pope, L E: 3 articles (08/2001 - 08/2000)|
|4.||Berg, James E: 2 articles (08/2002 - 08/2002)|
|5.||Hlywka, Jason J: 2 articles (08/2002 - 08/2002)|
|6.||Tamarkin, Dov: 2 articles (08/2002 - 08/2002)|
|7.||Pope, Laura E: 2 articles (08/2002 - 08/2002)|
|8.||Iglesias, Guadalupe: 2 articles (08/2002 - 08/2002)|
|9.||Berg, J E: 2 articles (08/2001 - 01/2001)|
|10.||Gunnill, L B: 2 articles (08/2001 - 01/2001)|
|1.||Herpes Labialis (Fever Blister)
11/01/1996 - "To demonstrate the efficacy of n-docosanol 10% cream in the treatment of recurrent herpes labialis, a randomised, double-blind, parallel group, placebo-controlled study was undertaken in 63 patients. "
11/01/1996 - "n-Docosanol 10% cream in the treatment of recurrent herpes labialis: a randomised, double-blind, placebo-controlled study."
04/01/2010 - "All of the published literature relating to docosanol and its use for the management of recurrent herpes labialis was reviewed, from the first report of docosanol to 31 January 2010. "
04/01/2010 - "Topical n-docosanol for management of recurrent herpes labialis."
12/01/2004 - "Docosanol is the first topical antiviral approved for over-the-counter use in recurrent herpes labialis."
09/01/2001 - "Two experiments with n-docosanol cream failed to show statistically significant differences by any parameter between n-docasonol cream and vehicle control-treated sites or between n-docosanol and untreated infection sites. "
12/01/1998 - "n-Docosanol-treated cells resist infection by a variety of lipid-enveloped viruses including the herpesviruses. "
07/01/1996 - "n-Docosanol is under development for HSV infections, and cidofovir is being developed for both HSV and CMV infections, as well as for treatment of other viral diseases. "
09/01/2001 - "Comparison of new topical treatments for herpes labialis: efficacy of penciclovir cream, acyclovir cream, and n-docosanol cream against experimental cutaneous herpes simplex virus type 1 infection."
|4.||Body Weight (Weight, Body)
08/01/2002 - "The no-observed-adverse-effect-level (NOAEL) for behenyl alcohol was 1000 mg/kg body weight/day for rats, and 2000 mg/kg body weight/day for dogs, the highest doses used in these studies."
08/01/2002 - "In two subchronic toxicity studies, CD rats and beagle dogs were administered behenyl alcohol by oral gavage for at least 26 weeks at doses of 0, 10, 100, or 1000 mg behenyl alcohol/kg body weight/day for rats and 0, 20, 200, or 2000 mg behenyl alcohol/kg body weight/day for dogs. "
08/01/2002 - "Compound-related effects in dogs were limited to observations of pale feces, indicative of unabsorbed behenyl alcohol, at doses of 2000 mg/kg body weight/day. "
08/01/2002 - "The observation of pale feces was the only compound-related effect reported, limited to rabbits treated with 2000 mg behenyl alcohol/kg body weight. "
08/01/2002 - "Similarly, behenyl alcohol had no reproductive effects on rabbits treated with doses up to 2000 mg/kg body weight. "
|5.||Kaposi Sarcoma (Kaposi's Sarcoma)
01/01/2001 - "These observations led us to conduct a pilot clinical study with docosanol 10% cream as a topical treatment for Kaposi's sarcoma (KS) in HIV-1-infected patients. "
01/01/2001 - "The antiviral drug docosanol as a treatment for Kaposi's sarcoma lesions in HIV type 1-infected patients: a pilot clinical study."
01/01/2001 - "These results suggest that docosanol merits further investigation as a potential topical therapy in the treatment of AIDS-associated Kaposi's sarcoma lesions."
|3.||Polyethylene Glycols (Polyethylene Glycol)
|5.||Phenol (Carbolic Acid)
|6.||Excipients (Suspending Agents)
|8.||stearic acid (magnesium stearate)